PMID- 16980004
OWN - NLM
STAT- MEDLINE
DCOM- 20061208
LR  - 20161124
IS  - 0041-1345 (Print)
IS  - 0041-1345 (Linking)
VI  - 38
IP  - 7
DP  - 2006 Sep
TI  - Effects of azathioprine and mycophenolate mofetil-immunosuppressive regimens on 
      the erythropoietic system of renal transplant recipients.
PG  - 2077-9
AB  - INTRODUCTION: Azathioprine (AZA) and mycophenolate mofetil (MMF) are major 
      immunosuppressants used to prevent rejection following renal transplantation. 
      Bone marrow suppression is a potential adverse effect of these agents manifesting 
      itself as leukopenia, thrombocytopenia, and anemia. The aim of this study was to 
      compare the effects of AZA versus MMF immunosuppressive regimens on the 
      erythropoietic system of renal transplant recipients within 6 months after 
      transplantation. METHODS: Eighty kidney allograft recipients who were on AZA (n = 
      40) or MMF (n = 40) plus cyclosporine and prednisolone were enrolled in this 
      study. Hematologic parameters included red blood cell counts, hemoglobin (Hb), 
      hematocrit, mean corpuscular volume, mean corpuscular hemoglobin (MCH) and mean 
      corpuscular hemoglobin concentration (MCHC) and were measured before and at 1 
      week, as well as 1 and 6 months posttransplantation. Plasma erythropoietin level 
      was measured at the end of 6 months. Statistical analysis was performed with 
      Student t test; a P value less than .05 was considered significant. RESULTS: 
      There was no significant difference between the two groups regarding red blood 
      cell counts. High Hb level was noted at 1 and 6 months posttransplantation among 
      patients who received MMF. MCH and MCHC were higher among patients on MMF 
      compared with those on AZA at 1 week and 1 month posttransplant. Although the 
      mean plasma erythropoietin levels in AZA-treated patients were higher than those 
      of MMF-treated patients, the trend did not reach statistical significance (P = 
      .066). CONCLUSION: MMF administration was apparently associated with a higher 
      level of hemoglobin compared with AZA among renal allograft recipients with good 
      graft function at 6 months posttransplantation.
FAU - Khosroshahi, H T
AU  - Khosroshahi HT
AD  - Department of Nephrology, Dialysis and Renal Transplantation, Kidney 
      Transplantation Center, Imam Hospital, Tabriz University of Medical Sciences, 
      Daneshgah St. Tabriz, Iran. drtayebikh@yahoo.com
FAU - Asghari, A
AU  - Asghari A
FAU - Estakhr, R
AU  - Estakhr R
FAU - Baiaz, B
AU  - Baiaz B
FAU - Ardalan, M R
AU  - Ardalan MR
FAU - Shoja, M M
AU  - Shoja MM
LA  - eng
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Hemoglobins)
RN  - 0 (Immunosuppressive Agents)
RN  - 11096-26-7 (Erythropoietin)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - HU9DX48N0T (Mycophenolic Acid)
RN  - MRK240IY2L (Azathioprine)
SB  - IM
MH  - Azathioprine/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Erythrocyte Count
MH  - Erythropoiesis/*drug effects
MH  - Erythropoietin/*blood
MH  - Follow-Up Studies
MH  - Hematocrit
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Kidney Transplantation/immunology/*physiology
MH  - Mycophenolic Acid/*analogs & derivatives/therapeutic use
MH  - Prednisolone/therapeutic use
MH  - Transplantation, Homologous
EDAT- 2006/09/19 09:00
MHDA- 2006/12/12 09:00
CRDT- 2006/09/19 09:00
PHST- 2006/09/19 09:00 [pubmed]
PHST- 2006/12/12 09:00 [medline]
PHST- 2006/09/19 09:00 [entrez]
AID - S0041-1345(06)00661-0 [pii]
AID - 10.1016/j.transproceed.2006.06.043 [doi]
PST - ppublish
SO  - Transplant Proc. 2006 Sep;38(7):2077-9. doi: 10.1016/j.transproceed.2006.06.043.